
Viropharma Inc Profile last edited on: 6/15/21
CAGE: 44SP4
UEI: MGHZQ16KEN33
Business Identifier: Small-molecule therapeutics for RNA virus-caused diseases: antivir Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 06
County: Chester
Congr. District: 06
County: Chester
Public Profile
In November 2013, Viropharma was acquired by Shire PLC. News reports at the time suggested that that purchase was primarily due to SHire's decision to acquire the orphan drug Cinryze, a drug developed by Viropharma for the inflammatory condition hereditary angioedema, and which complemented Shireâs Firazyr for the same malady. Involved in SBIR from soon after its founding in 1994, ViroPharma is a development stage pharmaceutical company committed to the commercialization, development and discovery of new antiviral medicines. Its current drug development and discovery activities are focused on a number of ribonucleic acid (RNA) virus diseases, including viral meningitis, viral respiratory infection, the common cold, respiratory syncytial virus pneumonia and hepatitis C. ViroPharma's most advanced product candidate, pleconaril, is being developed for the treatment of common RNA virus diseases. ViroPharma has completed a Phase II challenge study in viral respiratory infection (VRI) with pleconaril, in which all evaluated disease measures were significantly reduced in treated subjects, along with another Phase II clinical trial for viral meningitis which demonstrated that pleconaril significantly reduced disease duration
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
250-500Revenue Range
20M-50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : VPHMIP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
1996 | 1 | NIH | $100,000 | |
Project Title: Hepatitis C Virus RNA Helicase Genotypes | ||||
1995 | 1 | NIH | $90,813 | |
Project Title: Drug Screening Assay for Hepatitis C Virus RNA Helicase |
Key People / Management
Michel De Rosen -- President
Marc S Collett
James M Groarke
Robert Jordan
Vincent J Milano -- Chief Executive Officer
Claude H Nash -- Founder; Chief Executive Officer; Chairman
Charles A Rowland Jr -- Vice President; Chief Financial Officer
Daniel B Soland -- Chief Operating Officer
Marc S Collett
James M Groarke
Robert Jordan
Vincent J Milano -- Chief Executive Officer
Claude H Nash -- Founder; Chief Executive Officer; Chairman
Charles A Rowland Jr -- Vice President; Chief Financial Officer
Daniel B Soland -- Chief Operating Officer